{"doi":"10.3390/v14040670","title":"Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir","abstract":"The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus control selected from a total of 99 patients recovered from moderate COVID-19. These subjects participated in the longitudinal (>6 months) analysis of (i) SARS-CoV-2 spike protein’s receptor-binding domain IgG, (ii) virus neutralization assay using authentic virus, and (iii) neutralization potency against original (WT) SARS-CoV-2 and cross-neutralization against B.1.351 (beta) variant carrying triple mutations of K417N, E484K, and N501Y. The results demonstrate that the use of favipiravir: (1) significantly accelerated the elimination of SARS-CoV-2 in the case vs. control groups (p = 0.027), (2) preserved the generation and persistence of neutralizing antibodies in the host, and (3) did not interfere the maturation of neutralizing potency of anti-SARS-CoV-2 and neutralizing breadth against SARS-CoV-2 variants. In conclusion, treatment of COVID-19 with favipiravir accelerates viral clearance and does not interfere the generation or maturation of neutralizing potency against both WT SARS-CoV-2 and its variants.","journal":"Viruses","year":2022,"id":287298,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7989,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":881059,"name":"Takashi Sato","orcid":"0000-0002-2676-3781","position":1,"is_corresponding":false},{"id":72612,"name":"Saya Moriyama","orcid":"0000-0003-2057-9198","position":2,"is_corresponding":false},{"id":516059,"name":"Yu Adachi","orcid":"0000-0002-8573-987X","position":3,"is_corresponding":false},{"id":966932,"name":"Masahiro Shinoda","orcid":"0000-0002-0288-5637","position":4,"is_corresponding":false},{"id":966933,"name":"Shinichiro Ota","orcid":"0000-0002-0922-8656","position":5,"is_corresponding":false},{"id":967349,"name":"Miwa Morikawa","orcid":null,"position":6,"is_corresponding":false},{"id":966934,"name":"Masamichi Mineshita","orcid":"0000-0002-6933-6579","position":7,"is_corresponding":false},{"id":966935,"name":"Takayuki Matsumura","orcid":"0000-0003-1760-3484","position":8,"is_corresponding":false},{"id":251515,"name":"Yoshimasa Takahashi","orcid":"0000-0001-6342-4087","position":9,"is_corresponding":false},{"id":966936,"name":"Masaharu Shinkai","orcid":"0000-0002-4012-2518","position":10,"is_corresponding":false},{"id":966931,"name":"Kanako Shinada","orcid":"0000-0002-0697-6659","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T00:29:56.781756Z","pmid":"35458400","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}